ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,304.72
0.70%
US Tech 100
18,318.00
0.95%
다우존스 지수
39,069.59
0.01%
Bitcoin
68,392.68
-0.17%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Vistagen Therapeutics Inc (VTGN)

  7. Vistagen Therapeutics Inc (VTGN) 뉴스

VTGN

Vistagen Therapeutics (VTGN)

Vistagen Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:VTGN
일자시간출처헤드라인심볼기업
2024/05/2321:30Business WireVistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
2024/05/0721:30Business WireVistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
2024/04/2521:30Business WireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueNASDAQ:VTGNVistagen Therapeutics Inc
2024/04/0921:30Business WireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
2024/04/0121:30Business WireVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2NASDAQ:VTGNVistagen Therapeutics Inc
2024/03/1121:30Business WireVistagen to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VTGNVistagen Therapeutics Inc
2024/03/0708:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/03/0708:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/03/0708:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/03/0708:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/03/0114:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/2822:30Business WireVistagen to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1508:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1506:51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1422:56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1406:52Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1406:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1406:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1406:20Business WireVistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/1308:27Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VTGNVistagen Therapeutics Inc
2024/02/0622:30Business WireVistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024NASDAQ:VTGNVistagen Therapeutics Inc
2024/01/0407:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/01/0407:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
2024/01/0407:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
2023/12/2722:30Business WireVistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic PainNASDAQ:VTGNVistagen Therapeutics Inc
2023/11/1006:44Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistagen Therapeutics Inc
2023/11/1006:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
2023/11/1006:30Business WireVistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial ResultsNASDAQ:VTGNVistagen Therapeutics Inc
2023/11/0822:30Business WireVistagen to Present at Stifel 2023 Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
2023/11/0722:30Business WireVistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific ConferencesNASDAQ:VTGNVistagen Therapeutics Inc
 검색 관련기사 보기:NASDAQ:VTGN

최근 히스토리

LSE
TSWE
Vaneck Esg Ew
BIT
S29330
Societe Generale Effekten
NASDAQ
NUBI
Nubia Brand
UNSW3
WBGLUSDT
Wrapped BGL
LSE
0OMU
Snaige Ab
LSE
ADMR
Admiral Acquisition
ASX
MRDOA
Mount Ridley Mines
BIT
UC24CZ
Unicredit Bank
AMEX
MGK
Vanguard Mega Cap Growth...
LSE
76QW
Op Corp Bank.27
COIN
BSTGBP
BlockStamp
NASDAQ
GOEVW
Canoo
LATK
GARIUSDT
Gari Network
COIN
FLPEUR
DOWI
DJUSHC
DJ US Health Care
LSE
AJ86
Utd Utl Wt F 46
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유